[Infections and liver cirrhosis]

Area of Science:

• Hepatology
• Infectious Diseases
• Immunology

Background:

• End-stage liver disease (ESLD) is a critical condition characterized by immune dysfunction.
• Patients with ESLD exhibit increased susceptibility to bacterial, fungal, and viral infections.
• Infections in ESLD significantly elevate morbidity and mortality rates.

Purpose of the Study:

• To highlight the prevalence and challenges of infections in end-stage liver disease.
• To emphasize the growing threat of multidrug-resistant organisms in this patient population.
• To underscore the necessity for improved prevention, early detection, and treatment strategies for infections in ESLD.

Main Methods:

• Literature review and analysis of infection prevalence in end-stage liver disease patients.
• Examination of current treatment challenges posed by multidrug-resistant organisms.
• Synthesis of data on infection-related complications and outcomes in ESLD.

Main Results:

• Bacterial infections are the most common, affecting nearly 30% of end-stage liver disease patients.
• Multidrug-resistant organisms present significant hurdles in managing infections.
• Infections are a major contributor to adverse outcomes in end-stage liver disease.

Conclusions:

• Effective management of infections in end-stage liver disease requires urgent attention.
• Enhanced prevention, early diagnosis, and broad-spectrum treatment options are essential.
• Combating multidrug-resistant organisms is critical for improving survival in ESLD patients.